ERGOMED

Ergomed is a global pharmaceutical services organization (PSO) specializing in providing clinical research and drug development services to the biotechnology and pharmaceutical industries. The company offers a comprehensive suite of services, including clinical trial management, data management, biostatistics, medical writing, pharmacovigilance, and regulatory affairs across Phases I-IV of clinical development. Ergomed has built particular expertise in complex therapeutic areas such as oncology, neurology, and rare diseases. Founded in 1997, Ergomed established a significant international presence, including an operational hub in Sofia, Bulgaria, which supports its clinical development activities in the Central and Eastern European region. The company is recognized for its commitment to accelerating drug development for its clients through operational excellence and a strategic focus on specific disease areas. Historically, Ergomed was publicly listed on the London Stock Exchange's AIM market and was known for its innovative co-development model, where it would invest its services in promising biotech projects in exchange for future revenue shares. In 2023, Ergomed was acquired by Permira, a global private equity firm, transitioning the company into private ownership while continuing its core mission as a key service provider in the biopharmaceutical sector.

Last researched: 3/29/2026

0 of 7 listings flagged by automated signals